Curanex Pharmaceuticals (CURX)
Develops a botanical drug candidate for ulcerative colitis and inflammatory diseases.
Something off on this page? Send us feedback.
Develops Phyto-N, a single-plant botanical extract, for ulcerative colitis and other immune and inflammatory diseases. The preclinical program has no product revenue and relies on FDA clearance, external development partners, financing, and consistent botanical-material quality.
Develops Phyto-N, a proprietary single-plant botanical extract, as a drug candidate for ulcerative colitis and other immune and inflammatory diseases. It has no approved product or product revenue; if approved, it identifies drug sales, licensing and collaborations, and research grants or contracts as possible revenue channels.
Combines traditional-use observations with chemistry, manufacturing and controls, animal studies, and FDA-required development work. Its scientific work spans U.S. and Chinese institutions, while FDA review is its initial regulatory path and Australia is the intended initial human-trial location. Phyto-N is its only identified candidate, and the organization relies on CROs and contract development and manufacturing organizations for clinical supply and much of its development work.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.9M · Total debt $276.4K · Total assets $5.1M · Shareholders' equity $4.8M
- Revenue
- $0
- Operating income
- −$3.3M
- Net income
- −$3.3M
No dividends on record.
| Institutions8 holders · as of Mar 31, 2026 | 1.04% | 16.4K shares | |
| Insiders2 holders · as of Sep 2, 2025 | 45.55% | 714.3K shares | |
| Otherremainder | 53.41% | 837.5K shares |
1.57M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (1.57M in the company's Sep 3, 2026 report, 1.42M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Chang LiuInsider10 percent owner | 22.99% | 360,501 | Form 4filed Sep 2, 2025 ↗ |
Dian Ying Jing1Insider10 percent owner, officer: Secretary | 22.56% | 353,808 | Form 4filed Sep 2, 2025 ↗ |
Geode Capital Management, LLCInstitution | 0.35% | 111,130 | 13Fas of Mar 31, 2026 |
Two Sigma Securities, LLCInstitution | 0.18% | 56,651 | 13Fas of Mar 31, 2026 |
XTX Topco LtdInstitution | 0.16% | 51,289 | 13Fas of Mar 31, 2026 |
| See all 11 → | |||
- Dian Ying Jing reports a block also reported by Jun Liu; it is counted once, under Jun Liu.
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- AbbVie
Broadest direct UC and atopic-dermatitis overlap through Rinvoq.
- Pfizer
Oral UC and atopic-dermatitis therapies, plus a cachexia program.
- Takeda (ADR)
Entrenched, leading UC therapy with scale in gastroenterology.
- Eli Lilly
Approved UC biologic and atopic-dermatitis biologic franchise.
- Johnson & Johnson
Tremfya is a growing long-term ulcerative-colitis treatment franchise.
- Regeneron
Co-commercialized Dupixent anchors an entrenched AD position.
- Sanofi (ADR)
Dupixent partnership creates a leading atopic-dermatitis rival.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Curanex Pharmaceuticals | $4.55 | +1.11% | $6.4M | — | — | — | — |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Takeda (ADR) | $18.73 | +1.55% | $58.65B | 51.2 | 56.8 | 2.0 | +5.8% |
| Eli Lilly | $1,165.91 | +0.56% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Johnson & Johnson | $275.18 | −0.02% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Median | 38.9 | 20.2 | 5.7 | +10.2% |